The Phase 3 clinical trial investigating dapagliflozin for its effect on myocardial fibrosis and ventricular function in patients who have experienced a ST-segment elevation myocardial infarction (STEMI) reached its primary completion on March 31, 2025. This study, known as DAPA-STEMI, enrolled 54 participants to evaluate the potential benefits of this treatment.

Background

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2i). The DAPA-STEMI trial is designed to investigate whether this drug can reduce heart muscle scarring, also known as fibrosis, and improve heart function following a ST-segment elevation myocardial infarction (STEMI). This condition is a severe type of heart attack where the heart's main pumping chamber is damaged.

Trial design

The DAPA-STEMI study (NCT06619600) is a Phase 3, randomized trial that has completed primary data collection. It enrolled 54 participants aged 30-85 who had recently experienced a STEMI. The study's conditions of interest include ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure, and Myocardial Fibrosis. Participants were assigned to receive either dapagliflozin or a placebo. The trial uses cardiac MRI to measure changes in heart structure and function over six months, aiming to provide mechanistic insights into heart failure prevention after heart attacks.

What this means

The primary completion of the DAPA-STEMI trial signifies a crucial step towards understanding dapagliflozin's potential role in post-STEMI care. With primary data collection now complete, researchers can proceed with analyzing the collected information on myocardial fibrosis and ventricular function. The study's findings are anticipated to offer important mechanistic insights into strategies for preventing heart failure following heart attacks, potentially influencing future treatment guidelines for patients with STEMI.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06619600, titled "Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction," was updated to reflect primary completion on March 31, 2025, on clinicaltrials.gov.